secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001625297-25-000032
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 1.01, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing
--------------------------------------------------------------------------------

- Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.
- Mark Crossley stepped down as CEO and director; separation terms previously filed.
- Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.
- All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.
- New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/indv-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer